Coley Pharmaceutical Group, Inc.

University of Iowa Research Foundation

Coley Pharmaceutical Gmbh

Manistee Partners LLC

Sepracor, Inc.

Creative Biomolecules, Inc.

Selecta Biosciences, Inc.

Manistee Therapeutics, Inc.

Robert L Bratzler

Arthur Mertz Krieg

Frederick Ryckman

Martin Wand

Bradford J Shingleton

Charles M Cohen

Charles M Zepp

James S Huston

Grayson B Lipford

Gunther Hartmann

Lloyd Johnston

David R Dodds

Deanna M Petersen

Yves Fouron

Robert A Dishman

Provided herein are prostaglandin Fanalog compositions and methods for treating migraines.

Treatment of migraines

Provided herein are prostaglandin F2alpha analog compositions and methods for treating migraines by topical administration. The method involves administering topically to a subject in need thereof a composition including a prostaglandin F2apha analog or pharmaceutically acceptable salt thereof, in an amount effective to treat migraine. The treatment may be administered prophylactically or therapeutically. Topical administration is to the epidermis, conjunctival surface or other mucous membranes, typically to a nail, the skin, the hair, the surface of the eye or the inner surface of the eyelid, and the like. The prostaglandin F2a analog can be latanoprost, isopropyl unoprostone, bimatoprost, travoprost, or tafluprost; or pharmaceutically acceptable salt thereof.

Methods and compositions are provided for extending the clinical utility of IFN-&#x3b1; in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-&#x3b1; treatment and reduce IFN-&#x3b1; treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.

Methods related to immunostimulatory nucleic acid-induced interferon

The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

Immunostimulatory nucleic acids for the treatment of asthma and allergy

Disclosed are processes and apparatus for separating a desired solute, such as an optically active isomer, from a complex mixture using carrier facilitated transport in an immobilized liquid membrane or carrier facilitated solvent extraction. The carrier is a binding protein selected and/or engineered to immunochemically reversibly bind to the solute and to have a significant solubility in the extracting solvent or immobilized liquid membrane.

Separation by carrier mediated transport

Growing community of inventors

Concord, MA, United States of America

Robert L Bratzler